MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (March 2017)

37 slides from MabVax Therapeutics's investor presentation, Mar 31, 2017

  1. Slide 1: MabVax Therapeutics April 2017 Presentation

    Slide 1: MabVax Therapeutics April 2017 Presentation

    L NASDAQ: MBVX NY, | MabVax therapeutics Clinical Stage Immuno-Oncology Company Developing Unique Human Monoclonal Antibody- Based Products for Difficult to Treat Cancers April 2017 Presentation David Hansen, President and CEO

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and

  3. Slide 3: MabVax Therapeutics Overview

    Slide 3: MabVax Therapeutics Overview

    MABVAX THERAPEUTICS OVERVIEW Fully-human antibody discovery platform ation into al development Integrated approach to development Development pathway to Phase II studies Key collaborations Mi MabVax therapeutics Products discovered from immune responses of cancer patients vaccinated against their so

  4. Slide 4: Remarkable Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products

    Slide 4: Remarkable Clinical and Scientific Progress on Unique Therapeutic and Diagnostic Products

    REMARKABLE CLINICAL AND SCIENTIFIC PROGRESS ON UNIQUE THERAPEUTIC AND DIAGNOSTIC PRODUCTS MVT-5873 clinical trial demonstrates ear! safety and efficacy MVT-2163 clinical trial demonstrates early safety and specificity MVT-1075 clinical trial authorized by FDA Expansion to other cancers expressing sa

  5. Slide 5: MabVax Has Rich Pipeline of Product Candidates

    Slide 5: MabVax Has Rich Pipeline of Product Candidates

    MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Program MVT-5873 Therapeutic Monotherapy MVT-5873 Therapeutic Combination with soc MVT-2163 PET-Imaging MVT-1075 Radio- immunotherapy HuMab 5B1-ADC. HuMab 5B1- Fe Optimization Additional HuMab Antibodies in Early Development Mi MabVax therapeutics Indic

  6. Slide 6: Summary of Preclinical Data

    Slide 6: Summary of Preclinical Data

    SUMMARY OF PRECLINICAL DATA Mi MabVax NASDAQ: MBVX therapeutics 6

  7. Slide 7: Sialyl Lewis A as a Viable Target for Cancer Therapeutics

    Slide 7: Sialyl Lewis A as a Viable Target for Cancer Therapeutics

    SIALYL LEWISs4 — AS A VIABLE TARGET FOR CANCER THERAPEUTICS ¢@ HuMab-5B1 derived from a patient vaccinated with MabVax vaccine licensed from MSKCC CA19-9 detection in patients 4 @ Sialyl Lewis A antigen (SLEA or CA19-9) is the most frequently utilized and only Pancreas 92 validated serum marker for

  8. Slide 8: HuMab-5B1 Is Highly Specific to sLeA Antigen by Glycan Array Analysis

    Slide 8: HuMab-5B1 Is Highly Specific to sLeA Antigen by Glycan Array Analysis

    HUMAB-5B1 Is HIGHLY SPECIFIC TO SLE* ANTIGEN BY GLYCAN ARRAY ANALYSIS ‘Consortium for Functional Glycomics 1MVT-8873 (581) at 10vpimt. 2009 ste tre serie -~ } j e000 setter sete ° —— 7 rr a \ cycanmiccanay irr ne 1. Against a glycan array! of 465 distinct carbohydrates, HuMab-5B1 binds with specific

  9. Slide 9: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    Slide 9: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer A. Pancreatic ductal adenocarcinoma & B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary F. Breast

  10. Slide 10: Non-Clinical Safety Studies Supporting MVT-5873

    Slide 10: Non-Clinical Safety Studies Supporting MVT-5873

    NON-CLINICAL SAFETY STUDIES SUPPORTING MVT-5873 GLP in vitro tissue cross-reactivity studies with human and cynomolgus tissues ¢ Staining similar in human and cynomolgus providing toxicology species justification @ Staining observed in epithelial cell types and related extracellular mucus-like mater

  11. Slide 11: MVT-5873 Clinical Program Summary and Interim Data

    Slide 11: MVT-5873 Clinical Program Summary and Interim Data

    MVT-5873 CLINICAL PROGRAM SUMMARY AND INTERIM DATA Mi MabVax NASDAQ: MBVX therapeutics 1

  12. Slide 12: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer

    Slide 12: MVT-5873 Phase I Trial for PDAC & CA19-9 Positive Cancer

    MVT-5873 PHASE I TRIAL FOR PDAC & CA19-9 POSITIVE CANCER Open label, non-Randomized, Dose Escalation/Expansion Study Part 1: Single Agent Dose Escalation (gemcitabine/nab-paclitaxel) Stage 3 and 4 Patients With Progressive Disease Who Have Failed Other Treatment Options Newly Diagnosed Treatment Nai

  13. Slide 13: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels in Pancreatic Cancer Patients

    Slide 13: Interim Analysis Shows MVT-5873 Normalizes CA19-9 Levels in Pancreatic Cancer Patients

    INTERIM ANALYSIS SHOWS MVT-5873 NORMALIZES CA19-9 LEVELS IN PANCREATIC CANCER PATIENTS Circulating Levels of Antigen Normalized at Modest Doses of Antibody MVT-5873 Dose and Administration '% CA19-9 Reduction (>95%, Normal) Phe ghabeaae @ CA19-9 normalization post MVT-5873 administration appears to

  14. Slide 14: Clinical Results to Date (03/07/17) by Patient

    Slide 14: Clinical Results to Date (03/07/17) by Patient

    CLINICAL RESULTS TO DATE (03/07/17) BY PATIENT RECIST 1.1 RECIST 1.1 RECIST 1.1 —_ 9 of 25 Stable at cycles/1 RECIST Assessment Pe Patients 5 of 25 Stable at 4 cycles/2 RECIST Assessments 3 of 25 Stable at 3 cycles/3 RECIST Assessments i | I I oo. 4 5 6 7 8 Time since start of treatment (months) @ S

  15. Slide 15: Unmet Clinical Need for Maintenance Therapy

    Slide 15: Unmet Clinical Need for Maintenance Therapy

    UNMET CLINICAL NEED FOR MAINTENANCE THERAPY ¢ Unmet need to extend and reinforce favorable results with induction therapies — Emerging strategies for long term control include pauses in therapy, re-challenges, and maintenance therapy — Commonly employed strategies are: * Switch to non-cross-resistan

  16. Slide 16: Value of New Maintenance Therapy for Pancreatic Cancer

    Slide 16: Value of New Maintenance Therapy for Pancreatic Cancer

    VALUE OF NEW MAINTENANCE THERAPY FOR PANCREATIC CANCER ¢ Only one comparison product approved for second line therapy: Merrimack’s ONIVYDE — Liposomal irinotecan and used only in combination with fluorouracil and leucovorin — OS improvement to 6.1 mos. vs 4.2 mos. and PFS improvement to 3.1 mos. vs.

  17. Slide 17: MVT-2163 Clinical Program Summary and Interim Data

    Slide 17: MVT-2163 Clinical Program Summary and Interim Data

    MVT-2163 CLINICAL PROGRAM SUMMARY AND INTERIM DATA M MabVax NASDAQ: MBVX therapeutics Ad

  18. Slide 18: MVT-2163 Preclinical Development Efforts Have Translated into Positive Clinical Results

    Slide 18: MVT-2163 Preclinical Development Efforts Have Translated into Positive Clinical Results

    MVT-2163 PRECLINICAL DEVELOPMENT EFFORTS HAVE TRANSLATED INTO POSITIVE CLINICAL RESULTS ¢ Based on in-depth review of clinical literature and input from thought leaders MabVax developed a rationale for a translational preclinical development plan to define: — Time required to obtain optimal scan ima

  19. Slide 19: MVT-2163 Imaging Compared to Standard PET Agent

    Slide 19: MVT-2163 Imaging Compared to Standard PET Agent

    MVT-2163 IMAGING COMPARED TO STANDARD PET AGENT Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts JNM Rivers ‘The co-tegistration of FDG-PET and computed Acquired "Zr radiolabed-5B1 antibody (*°Z-5B1) tomography (CT) (left) and planar sections of PET image of the same mouse

  20. Slide 20: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent

    Slide 20: Phase I Trial Design of MVT-2163 ImmunoPET Imaging Agent

    PHASE I TRIAL DESIGN OF MVT-2163 IMMUNOPET IMAGING AGENT PANCREATIC CANCER AND OTHER CA19-9 MALIGNANCIES Open label, non-randomized, dose escalation/expansion study Patients can roll to MVT-5873 Monotherapy Trial lation and . Part 1: Dose lation MVT-2163 do: lone, Then combination with MVT- Addition

  21. Slide 21: Patient Example: MVT-2163 PET Images

    Slide 21: Patient Example: MVT-2163 PET Images

    PATIENT EXAMPLE: MVT-2163 PET IMAGES LIVER METASTASIS AT HIGH SUV AS EARLY AS Day 1 POST DOSE MVT-2163 PET & Diagnostic CT Image Correlation Demonstrating Target Specificity Liver metastases SUVmax 75.2, Multiple Nodes SUVmax 10.2 MVT-5873 47mg then 2h delay time MVT-2163 PET PET / Cr | 20h 141h Dia

  22. Slide 22: Significant Accumulation of Antibody on Targeted Cancer

    Slide 22: Significant Accumulation of Antibody on Targeted Cancer

    SIGNIFICANT ACCUMULATION OF ANTIBODY ON TARGETED CANCER MVT-2163 Accumulates on Target without interference by CA19-9 Levels Patient administered 3 mg MVT-2163 Patient administered 3 mg MVT- (no MVT-5873 loading dose) 2163 (47 mg MVT-5873 loading dose) 3 ry % 30 as Eos ? 5% a ver eson 21s = we Misin

  23. Slide 23: MVT-2163 Product Opportunity

    Slide 23: MVT-2163 Product Opportunity

    MVT-2163 PRODUCT OPPORTUNITY MVT-2163 images tumor lesions not identified by diagnostic CT Staging newly diagnosed PDAC patients for surgery is limited by CT resolution — Only 20% deemed eligible for surgery and majority found inoperable during surgery — Problem: Incomplete disease dissemination ide

  24. Slide 24: MVT-1075 Program Summary and Product Opportunity

    Slide 24: MVT-1075 Program Summary and Product Opportunity

    MVT-1075 PROGRAM SUMMARY AND PRODUCT OPPORTUNITY M MabVax NASDAQ: MBVX therapeutics 24

  25. Slide 25: MVT-1075 Is Designed to Attack Primary Tumor and Metastatic Sites

    Slide 25: MVT-1075 Is Designed to Attack Primary Tumor and Metastatic Sites

    MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES Attribute HuMab-5B1 Antibody CA19-9 is validated target for PDAC Effective Payload Lutetium radionuclide (7Lu) Multi-cell effective range for tumor cell killing Loading dose pharmacokinetics well established by MVT-2163 Aieses therape

  26. Slide 26: MVT-1075 Designed to Attack Primary Tumor and Metastatic Sites and Enhance Cell Death

    Slide 26: MVT-1075 Designed to Attack Primary Tumor and Metastatic Sites and Enhance Cell Death

    MVT-1075 Is DESIGNED TO ATTACK PRIMARY TUMOR AND METASTATIC SITES AND ENHANCE CELL DEATH ST MVT-5873-Linker-Toxin (RIT) a Highly specific HuMab-5B1 “dle A antibody % radionuclide demo: ate significant accumulation on tumor Effective therapeutic payload and multi-cell killing — M MabVax NASDAQ: MBVX

  27. Slide 27: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression

    Slide 27: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression

    MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION fe 377Lu-CHX-A"-DTPA-5B1 Biodistribution of !”7 Lu-CHX-A”-DTPA-5B1 © Control (PBS) = 5B1 2 set df 130 2 = 300uCi 120 & io] * RO 110. , Bth 3 400 3 N=8 for all groups ° 80 2 ry es B

  28. Slide 28: Manufacturing, Quality, Distribution Established for Clinical Program

    Slide 28: Manufacturing, Quality, Distribution Established for Clinical Program

    MANUFACTURING, QUALITY, DISTRIBUTION ESTABLISHED FOR CLINICAL PROGRAM AND PATHWAY FOR COMMERCIALIZATION @ MVT-1075 manufactured on a per patient basis ¢ Manufacturing established at experienced cGMP third party site ¢ Produced from a bulk conjugate intermediate as unit-of-use vials @ Process similar

  29. Slide 29: MVT-1075 Unique Product with Significant Value Proposition

    Slide 29: MVT-1075 Unique Product with Significant Value Proposition

    MVT-1075 UNIQUE PRODUCT WITH SIGNIFICANT VALUE PROPOSITION Single doses of MVT-1075 demonstrate tumor regression in Compelling preclinical animal models of PDAC MVT-2163 clinical data have establish dosimetry, target specificity and high SUV values Prognosis for PDAC still poor. Must target primary

  30. Slide 30: MVT-1075 Product Opportunity

    Slide 30: MVT-1075 Product Opportunity

    MVT-1075 PRODUCT OPPORTUNITY ¢ Reduce disease burden by making more patients eligible for surgery — Given to newly diagnosed patients either before or after chemotherapy to reduce primary tumor size/spread and eliminate metastatic sites ¢ Applicable for multiple cancer types that are positive for CA

  31. Slide 31: Value Proposition for a New Radioimmunotherapy for Pancreatic Cancer

    Slide 31: Value Proposition for a New Radioimmunotherapy for Pancreatic Cancer

    VALUE PROPOSITION FOR A NEW RADIOIMMUNOTHERAPY FOR PANCREATIC CANCER ¢ Algeta’s Xofigo for castration-resistant prostate cancer — Xofigo (radium Ra 223) is radiotherapeutic alpha particle emitting product — Approved in US in May 2013 and EU in November 2013 — Development and commercialization deal w

  32. Slide 32: Market Opportunity for HuMab 5B1

    Slide 32: Market Opportunity for HuMab 5B1

    MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS FOR MULTIPLE CANCERS Pancreatic Colon & Rectum Small Cell Lung Cancer Stomach Mi MabVax therapeutics 53,070 134,490 30,143 26,370 Deaths Yr /Y u 41,780 7.7% 49,119 65% 20,100 14% 10,730 31% ' Global Data Disease Reports Market Op

  33. Slide 33: Partnering Discussions

    Slide 33: Partnering Discussions

    PARTNERING DISCUSSIONS ¢ Active discussions with potential partners under CDA in progress. Multiple opportunities ¢ Antibody as targeting vehicle for development of a bi-specific, ADC or CAR-T product — Multiple domestic and Asian companies — Multiple indications ¢ Radioimmunotherapy product — Multi

  34. Slide 34: Key Milestones for Building Shareholder Value

    Slide 34: Key Milestones for Building Shareholder Value

    Key MILESTONES FOR BUILDING SHAREHOLDER VALUE ea sous | anor | sats m MVT-5873 Y Initiate dose Y Early readouton * Complete * Full Phase I trial Therapeutic escalation safety ies, PK, dose enrollment and result available Monotherapy Phase I Trial report at scientific * Launch Ph Ib for meeting pilot

  35. Slide 35: Robust Intellectual Property

    Slide 35: Robust Intellectual Property

    ROBUST INTELLECTUAL PROPERTY 14 issued patents and 3 pending applications in the U.S. ¢ 13 issued US patents and 1 pending US application covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ¢ 1 issued US patent and 2 pending US applications covering monoclonal antibod

  36. Slide 36: Strong Management Team and Board of Directors

    Slide 36: Strong Management Team and Board of Directors

    STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson, CMA Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Executive Vic

  37. Slide 37: MabVax Therapeutics Company Contacts

    Slide 37: MabVax Therapeutics Company Contacts

    Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts J. David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer dhansen@mabvax.com gregoryhanson@mabvax.com 858-500-8455 858-500-8457 Mu Vax NASDAQ: MBVX | 37

Source: SEC EDGAR · 8-K filed Mar 31, 2017

More decks from MabVax Therapeutics Holdings Inc